SCHEMBL16696294

SCHEMBL16696294

Clc1nc(N2CCCCC2)c2ccsc2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.66
MAPK1 P28482 2/20 0.66
HSD17B10 Q99714 2/20 0.66
KDM4E B2RXH2 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
ALDH1A1 P00352 1/20 0.46
CSNK2A2 P19784 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45
HTR2C P28335 3/20 0.43
PIK3CA P42336 2/20 0.42
PIK3CB P42338 2/20 0.42
MEN1 O00255 2/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 2/20 0.40
HPGD P15428 2/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
HTR1A P08908 1/20 0.39
MAT2A P31153 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190563 0.85 PIK3CA (0.58) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL27650338 0.81 MAPK1 (0.66) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL18072404 0.81 L3MBTL1 (0.66) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL13640916 0.74 HTR2C (0.72) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL16686183 0.74 L3MBTL1 (0.49) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL20589783 0.73 PDE4A (0.57) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL4781933 0.72 HTR2C (0.42) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL4439640 0.72 ADORA2A (0.44) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL20588533 0.72 ADORA2A (0.46) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2
SCHEMBL20588532 0.72 ADORA2A (0.46) L3MBTL1MAPK1HSD17B10KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 US disclosed
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity UNIV TEXAS (US) 2023-09-14 US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20210283113-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2021-09-16 US disclosed
US-20210106587-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY UNIV CASE WESTERN RESERVE (US) 2021-04-15 US disclosed
US-20210100778-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH THE UNIVERSITY OF IOWA 2021-04-08 US disclosed
US-10945998-B2 Inhibitors of short-chain dehydrogenase activity for treating fibrosis CASE WESTERN RESERVE UNIVERSITY (US) 2021-03-16 US disclosed
US-10869871-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2020-12-22 US disclosed
US-20190275014-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING CELL DEATH CASE WESTERN RESERVE UNIVERSITY (US) 2019-09-12 US disclosed
EP-3057973-B1 COMPOSITIONS COMPRISING A 15-PGDH INHIBITOR FOR THE HEALING OF WOUNDS UNIV CASE WESTERN RESERVE (US) 2019-09-04 EP disclosed
US-20180064694-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2018-03-08 US disclosed
US-20180064694-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2018-03-08 US disclosed
WO-2018017582-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH CASE WESTERN RESERVE UNIVERSITY (US) 2018-01-25 WO disclosed
US-9789116-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2017-10-17 US disclosed
US-9789116-B2 Compositions and methods of modulating short-chain dehydrogenase activity CASE WESTERN RESERVE UNIVERSITY (US) 2017-10-17 US disclosed
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-22 US disclosed
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-22 US disclosed
WO-2015065716-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY CASE WESTERN RESERVE UNIVERSITY (US) 2015-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136730-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS L3MBTL1 3738/4885MAPK1 3373/4885HSD17B10 21/4885
US-20210100778-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH HPGD, GCDH, DCX L3MBTL1 2294/4885MAPK1 433/4885HSD17B10 28/4885
US-20210106587-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS L3MBTL1 3738/4885MAPK1 3373/4885HSD17B10 21/4885
US-20230285402-A1 Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity HPGD, GCDH, HPGDS L3MBTL1 3738/4885MAPK1 3373/4885HSD17B10 21/4885
US-10869871-B2 Compositions and methods of modulating short-chain dehydrogenase activity HPGD, GCDH, HPGDS L3MBTL1 3738/4885MAPK1 3373/4885HSD17B10 21/4885
US-20190275014-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING CELL DEATH HPGD, DCX, GCDH L3MBTL1 2596/4885MAPK1 410/4885HSD17B10 27/4885
US-20180064694-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH L3MBTL1 3047/4885MAPK1 3429/4885HSD17B10 19/4885
US-20210283113-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH L3MBTL1 3047/4885MAPK1 3429/4885HSD17B10 19/4885
US-10945998-B2 Inhibitors of short-chain dehydrogenase activity for treating fibrosis GCDH, HPGD, UGDH L3MBTL1 3047/4885MAPK1 3429/4885HSD17B10 19/4885
US-20170173028-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS L3MBTL1 3738/4885MAPK1 3373/4885HSD17B10 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.